Expert Review of Anticancer Therapy最新文献_第4页

Key barriers in utilizing advanced T-cell engager strategies on solid tumors. 利用先进的t细胞接合器策略治疗实体瘤的关键障碍。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-07 DOI: 10.1080/14737140.2026.2730177

Bo Mi Ku, Sung-Won Lim, Jieun Uhm, Byeong-Bae Park, Myung-Ju Ahn

{"title":"Key barriers in utilizing advanced T-cell engager strategies on solid tumors.","authors":"Bo Mi Ku, Sung-Won Lim, Jieun Uhm, Byeong-Bae Park, Myung-Ju Ahn","doi":"10.1080/14737140.2026.2730177","DOIUrl":"10.1080/14737140.2026.2730177","url":null,"abstract":"Introduction: T cell engagers (TCEs) are engineered immune-mobilizing molecules that recruit T cells toward tumor cells. TCEs have demonstrated clinical efficacy in hematologic malignancies and currently show therapeutic potential in solid tumors through the approvals of tebentafusp and tarlatamab in uveal melanoma and small cell lung cancer. However, implementation of TCEs in solid tumors presents distinct challenges owing to tumor intrinsic features such as lack of specific antigens, biochemical and physical barriers that hinder T cell infiltration, complex immunosuppressive microenvironments, and intrinsic or acquired resistance to TCEs.Areas covered: This review aims to cover inclusive overview of the current portrait of TCEs for the treatment of solid tumors. It provides the mechanisms and design principle of TCE and addresses the challenges that impede treatment efficacy. Especially, we extensively depict the primary and acquired resistance mechanisms to TCEs. Moreover, we highlight the next-generation directions such as engineering of antibody format and combination strategies to overcome these challenges and improve the clinical efficacy.Expert opinion: Integrating logical target selection, advanced engineering, biomarker-guided patient stratification, and deliberate clinical design allows TCEs to successfully expand the reach of novel immunotherapeutics into solid tumors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":3.0,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

¹⁷⁷Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer. lupsma -617放射配体治疗前列腺癌的免疫调节剂作用。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-05-07 DOI: 10.1080/14737140.2026.2657914

Carolina Sciortino, Amedeo Nuzzo, Marco Stellato, Melanie Claps, Alessandro Rametta, Valentina Guadalupi, Eleonora Gusmaroli, Simone Rota, Federica Mascaro, Patrizia Giannatempo, Matteo Zimatore, Marco Maccauro, Veronica Huber, Elena Verzoni, Giuseppe Procopio

{"title":"177Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.","authors":"Carolina Sciortino, Amedeo Nuzzo, Marco Stellato, Melanie Claps, Alessandro Rametta, Valentina Guadalupi, Eleonora Gusmaroli, Simone Rota, Federica Mascaro, Patrizia Giannatempo, Matteo Zimatore, Marco Maccauro, Veronica Huber, Elena Verzoni, Giuseppe Procopio","doi":"10.1080/14737140.2026.2657914","DOIUrl":"10.1080/14737140.2026.2657914","url":null,"abstract":"Introduction: Metastatic castration-resistant prostate cancer (mCRPC) remains a therapeutic challenge despite advances in systemic treatments. Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with 177Lu-PSMA-617 has emerged as an effective strategy, and increasing evidence suggests that its activity may extend beyond direct cytotoxicity to the modulation of the tumor immune microenvironment.Areas covered: A narrative literature review was conducted using the PubMed database to identify relevant studies published up to January 2026. This review summarizes preclinical and clinical evidence on the immunomodulatory effects of PSMA-targeted RLT. We discuss how 177Lu-PSMA-617 influences immune cell populations, induces immunogenic cell death, and interacts with key microenvironmental factors such as hypoxia, vascularization, and PSMA heterogeneity. The role of alternative radioligands, including alpha-emitters and fibroblast activation protein-targeted agents, is also examined.Expert opinion: PSMA-targeted RLT represents a promising immune-priming modality in mCRPC, but its clinical impact is limited by tumor and microenvironmental heterogeneity. Biomarker-driven patient selection, optimized dosimetry, and rational combination strategies with immunotherapy will be essential to fully exploit its immunomodulatory potential and to achieve durable clinical benefit.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1105-1112"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns and survival in advanced/metastatic triple-negative breast cancer in Japan. 日本晚期/转移性三阴性乳腺癌的现实世界治疗模式和生存率

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-05-20 DOI: 10.1080/14737140.2026.2669336

Hitomi Sanno, Yuichiro Ito, Kazuko Taniguchi, Yuya Yoshimoto, Shigehira Saji

{"title":"Real-world treatment patterns and survival in advanced/metastatic triple-negative breast cancer in Japan.","authors":"Hitomi Sanno, Yuichiro Ito, Kazuko Taniguchi, Yuya Yoshimoto, Shigehira Saji","doi":"10.1080/14737140.2026.2669336","DOIUrl":"10.1080/14737140.2026.2669336","url":null,"abstract":"Aims: To gather information regarding treatment patterns, outcomes, and healthcare resource utilization (HCRU) for patients with advanced/metastatic triple-negative breast cancer (TNBC) in real-world clinical settings in Japan.Methods: From commercially available health claims databases, patients diagnosed with TNBC between April 2008 and August 2015 were categorized into those initially diagnosed with early-stage (Stage I-IIIB) TNBC who underwent surgery with or without perioperative treatments and subsequently experienced recurrence, and those initially diagnosed at Stage IV.Results: Among the 276 and 490 patients in the recurrence and Stage IV cohorts, systemic treatments were prescribed to 147 (53.3%) and 190 (38.8%) patients, respectively. Commonly used first-line treatments included capecitabine (20.4%), tegafur-gimeracil-oteracil (19.0%), and bevacizumab + paclitaxel (10.9%) (recurrence cohort); and bevacizumab + paclitaxel (19.5%), paclitaxel (12.1%), and 5-fluorouracil + epirubicin + cyclophosphamide (10.0%) (Stage IV cohort). Second- and third-line regimens were highly diverse. Time-to-treatment discontinuation decreased with advancing treatment lines. In the recurrence cohort without perioperative treatments, survival tended to be longer. Higher HCRU was observed with advancing treatment lines in the recurrence cohort, but not the Stage IV cohort.Conclusion: Treatments varied among Japanese patients diagnosed with recurrent and de novo Stage IV disease. These data may inform future real-world studies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1221-1235"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147962692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores. 高TDM评分的抗血管生成酪氨酸激酶抑制剂（TKIs）临床药代动力学和药效学的系统综述。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-04-16 DOI: 10.1080/14737140.2026.2657916

Abdul Wasay Sherazi, Muhammad Fawad Rasool, Zheng Jiao, Faleh Alqahtani

{"title":"A systematic review on clinical pharmacokinetics and pharmacodynamics of antiangiogenic tyrosine kinase inhibitors (TKIs) with high TDM scores.","authors":"Abdul Wasay Sherazi, Muhammad Fawad Rasool, Zheng Jiao, Faleh Alqahtani","doi":"10.1080/14737140.2026.2657916","DOIUrl":"10.1080/14737140.2026.2657916","url":null,"abstract":"Introduction: Tyrosine kinase inhibitor (TKI) drugs are used to treat various cancer types. This systematic review evaluates the published pharmacokinetic (PK) and pharmacodynamic (PD) parameters of TKI drugs with high therapeutic drug monitoring (TDM) scores in humans.Methods: A comprehensive computerized literature search of four internet databases was carried out until July 2025 for sunitinib, pazopanib, sorafenib, axitinib, and cabozantinib, and it provided 3192 articles, of which 56 met the inclusion criteria by providing human PK and related PD information.Results: The exposure of TKI drugs generally increases with the dose escalation, as reflected by higher area under the curve from zero to infinity (AUC0-∞) and maximum plasma concentration (Cmax). In pediatric patients, sunitinib showed dose-dependent increases in exposure. Cabozantinib 140 mg showed higher exposure under fed versus fasted conditions, with AUC0-∞ increasing from 60,700 to 95,200 ng·h/ml and Cmax from 505 to 709 ng/ml. In pediatric gastrointestinal stromal tumor patients, sunitinib exhibited a large apparent volume of distribution (V/F) 3160 L, indicating extensive tissue distribution.Conclusion: This review summarizes clinical PK, drug-drug interaction studies, effects of dosage form on PK, and corresponding PD parameters of TKI drugs supporting PK models development for optimizing dosing regimens.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251110777.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1157-1174"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study. 定量和定性粪便免疫化学试验在哈萨克斯坦大肠癌筛查中的比较研究。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-05-08 DOI: 10.1080/14737140.2026.2671250

Abay Jumanov, Dilyara Kaidarova, Alma Zhylkaidarova, Innara Turkpenova, Ainash Oshibayeva, Yernar Myrzakulov

{"title":"Quantitative and qualitative fecal immunochemical tests for colorectal cancer screening in Kazakhstan: a comparative study.","authors":"Abay Jumanov, Dilyara Kaidarova, Alma Zhylkaidarova, Innara Turkpenova, Ainash Oshibayeva, Yernar Myrzakulov","doi":"10.1080/14737140.2026.2671250","DOIUrl":"10.1080/14737140.2026.2671250","url":null,"abstract":"Background: Late diagnosis of colorectal cancer (CRC) remains a public health challenge due to limitations in screening programs. This study evaluated the fecal immunochemical test (FIT) as an alternative screening method for CRC detection.Research design and methods: Colonoscopy and immunochemical analysis were used as standard diagnostics. A population-based survey in Kazakhstan assessed disease prevalence and screening outcomes. Diagnostic accuracy and prognostic value of haemoccult testing were analyzed, comparing quantitative and qualitative results.Results: Among 6,000 participants, 9.76% (n = 586) had positive FIT results. Elevated fecal hemoglobin concentrations (≥100 µg Hb/g stool) were found in 3.6% (n = 217), while 96.4% (n = 5786) had lower values. Of 150 clinically significant positive cases, 55 were confirmed, including 5 CRC cases and precancerous conditions. FIT facilitated large-scale screening. The Positive Predictive Value (PPV) for qualitative FIT was 10.4%, and for quantitative FIT (≥100 µg Hb/g), it was 15.7%. The Negative Predictive Value (NPV) for qualitative FIT was 100%, and for quantitative FIT, 99.5%.Conclusion: FIT demonstrates practical value as an efficient screening tool for early CRC detection, with a weak but significant correlation to histological findings (p < 0.01).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1237-1244"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147835521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B? 低危乙型肝炎患者是否可以考虑停止肝细胞癌监测？

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-03-30 DOI: 10.1080/14737140.2026.2651251

Nicole J Kim, H Nina Kim, Brian J McMahon, Lesleigh Kowalski Frank, George N Ioannou

{"title":"Can we consider stopping hepatocellular carcinoma surveillance in low-risk patients with hepatitis B?","authors":"Nicole J Kim, H Nina Kim, Brian J McMahon, Lesleigh Kowalski Frank, George N Ioannou","doi":"10.1080/14737140.2026.2651251","DOIUrl":"10.1080/14737140.2026.2651251","url":null,"abstract":"Introduction: Chronic hepatitis B (CHB) can cause liver cirrhosis and hepatocellular carcinoma (HCC). HCC surveillance with an abdominal ultrasound and serum alpha-fetoprotein every six months is recommended for patients with cirrhosis and in a subset of patients with non-cirrhotic CHB. However, it can be difficult to determine which patients are at high- vs. low-risk for HCC.Areas covered: We review the key factors that contribute to HCC risk in CHB, the concept of risk-based HCC surveillance, and some of the existing clinical tools that can be used to estimate HCC risk in CHB.Expert opinion: Individualized HCC risk estimates can help clinicians stratify patients into high- and low-risk groups, enabling tailored surveillance strategies. However, the practical use of existing tools remains limited by the lack of wide validation, variability in access to laboratory testing, and the inability to accurately predict dynamic changes in HCC risk over time. For most patients with CHB, HCC risk remains sufficiently high enough to justify ongoing HCC surveillance. However, in select low-risk patients, surveillance may be delayed or stopped with regular reassessment of HCC risk and shared decision-making, given the limitations of existing tools and the likelihood of changes in HCC risk over time.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1093-1104"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147581019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis. 新辅助治疗方案与三阴性乳腺癌病理完全缓解相关：系统回顾和网络荟萃分析。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-04-30 DOI: 10.1080/14737140.2026.2665835

Brenda Luana Rocha Soares Menegat, Ana Luíza Rocha Soares Menegat, Maria Victória Ferreira Piccoli, Luana Diniz Guerra Braz, Thiago Gorayeb Rebelo, Francisco Cezar Aquino de Moraes

{"title":"Neoadjuvant treatment regimens associated with pathological complete response in triple-negative breast cancer: a systematic review and network meta-analysis.","authors":"Brenda Luana Rocha Soares Menegat, Ana Luíza Rocha Soares Menegat, Maria Victória Ferreira Piccoli, Luana Diniz Guerra Braz, Thiago Gorayeb Rebelo, Francisco Cezar Aquino de Moraes","doi":"10.1080/14737140.2026.2665835","DOIUrl":"10.1080/14737140.2026.2665835","url":null,"abstract":"Introduction: Triple-negative breast cancer (TNBC) lacks estrogen, progesterone, and HER2 receptors, limiting treatment options. Neoadjuvant anthracycline- and taxane-based chemotherapy remains standard, achieving pathological complete response (pCR) rates of approximately 30%. We compared neoadjuvant treatments for early-stage TNBC using a systematic review and network meta-analysis (NMA).Methods: PubMed, EMBASE, and Cochrane were searched for randomized and observational studies of neoadjuvant treatment in TNBC. Odds ratios (OR) with 95% confidence intervals were pooled using a random-effects model. Certainty of evidence was assessed with GRADE. Statistical analyses were performed using RStudio.Results: Thirty-seven studies with 7683 patients were included. Twenty-five treatment nodes were formed, with paclitaxel (P) or docetaxel (D) + anthracycline-based (A) chemotherapy as the main comparator. Compared with PA-based + cyclophosphamide, higher pCR rates were observed with PA-based + carboplatin + pembrolizumab + cyclophosphamide (OR 3.04) and PA-based + carboplatin + veliparib + cyclophosphamide (OR 2.67). When DA-based + cyclophosphamide was the comparator, DA-based + cyclophosphamide + bevacizumab (OR 1.67) increased pCR. The SUCRA ranked PA-based + carboplatin + pembrolizumab, paclitaxel + carboplatin + atezolizumab, and DA-based + lobaplatin as most effective.Conclusions: Platinum agents, PARP inhibitors, and immune checkpoint inhibitors were associated with higher pCR rates in early-stage TNBC.Protocol registration: CRD42025640277.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1175-1190"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response. 可切除胃癌新辅助化疗后生存的决定因素：辅助剂量强度、放疗和病理反应。

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-04-13 DOI: 10.1080/14737140.2026.2657911

Özgecan Dülgar Kaya, Ayberk Bayramgil, Ahmet Bilici, Erdem Sünger, Tuğba Kaya, Tuğba Başoğlu Tüylü, Tuba Baydaş, Sinan Koca, Yeşim Ağyol, Selver Işık, Burçin Çakan Demirel, Vedat Buğra Erol, Nilufer Bulut, Busra Niğdelioğlu, Melike Özçelik

{"title":"Determinants of survival after neoadjuvant chemotherapy in resectable gastric cancer: adjuvant dose intensity, radiotherapy, and pathologic response.","authors":"Özgecan Dülgar Kaya, Ayberk Bayramgil, Ahmet Bilici, Erdem Sünger, Tuğba Kaya, Tuğba Başoğlu Tüylü, Tuba Baydaş, Sinan Koca, Yeşim Ağyol, Selver Işık, Burçin Çakan Demirel, Vedat Buğra Erol, Nilufer Bulut, Busra Niğdelioğlu, Melike Özçelik","doi":"10.1080/14737140.2026.2657911","DOIUrl":"10.1080/14737140.2026.2657911","url":null,"abstract":"Background: Neoadjuvant chemotherapy (NACT) is the standard of care for locally advanced gastric cancer, but adjuvant therapy is not tailored to pathological response and outcomes are poor. This study evaluated the impact of adjuvant chemotherapy (ACT) dose intensity, radiotherapy, and pathologic factors on disease-free survival (DFS) and overall survival (OS).Methods: A total of 197 patients with locally-advanced gastric cancer treated with NACT followed by gastrectomy from seven cancer centers were analyzed. Clinical, surgical, and pathological data were extracted. ACT regimens, dose-reductions, and receiving radiotherapy were recorded. Primary outcomes were DFS and OS. Kaplan-Meier and Cox-models were used to identify predictors of survival.Results: Most patients received FLOT (84.8%) as NACT and D2-lymphadenectomy. Full-dose ACT was delivered to 66.1%. At 24 months, DFS and OS were 77.1% and 84.1% with full-dose ACT versus 35.8% and 63.6% with reduced-dose ACT. Dose reduction independently increased recurrence risk (HR 4.73) and mortality (HR 2.84). Positive margins, higher ypT/ypNstage, <50% tumor-regression, lymphovascular and perineural invasion were associated with shorter DFS. Adjuvant radiotherapy did not significantly improve survival outcomes.Conclusions: Reduced-dose ACT after NACT and surgery was associated with inferior DFS and OS, indicating that maintaining full-dose adjuvant therapy is critical. These findings are limited by retrospective design; prospective response-adapted trials are needed.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1191-1199"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147638360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer. 派姆单抗谷浓度监测及其与晚期非小细胞肺癌预后的关系

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-05-05 DOI: 10.1080/14737140.2026.2668466

Ioannis P Trontzas, Anastasia Palaiologou, Natalia Kamperi, Anastasia Georganta, Emmanouil Panagiotou, Ioanna-Maria Orfanou, Konstantinos G Kyriakoulis, Ioannis Vathiotis, Elias A Kotteas, Dimitra Grapsa, Constantin Tamvakopoulos, Konstantinos N Syrigos

{"title":"Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer.","authors":"Ioannis P Trontzas, Anastasia Palaiologou, Natalia Kamperi, Anastasia Georganta, Emmanouil Panagiotou, Ioanna-Maria Orfanou, Konstantinos G Kyriakoulis, Ioannis Vathiotis, Elias A Kotteas, Dimitra Grapsa, Constantin Tamvakopoulos, Konstantinos N Syrigos","doi":"10.1080/14737140.2026.2668466","DOIUrl":"10.1080/14737140.2026.2668466","url":null,"abstract":"Background: Therapeutic drug monitoring (TDM) of immune checkpoint inhibitors (ICIs) remains limited due to drug-related challenges; however, a better understanding of exposure-effect relationships may improve antitumor activity and reduce immune-related adverse events (irAEs).Methods: We conducted a prospective TDM study measuring pembrolizumab trough concentrations (Cmin) using a commercial ELISA kit in 31 patients with advanced non-small cell lung cancer (NSCLC) receiving pembrolizumab monotherapy. Serial Cmin measurements were obtained at baseline (T0), before cycle 2 (T1), and at 3 (T2), 6 (T3), and 12 months (T4). Baseline clinicopathologic and serologic variables were recorded. Patients were followed for 2 years to assess treatment outcomes.Results: Pembrolizumab Cmin increased significantly over time (p < 0.0001), with the greatest rise after T2 (T1 vs. T2, p < 0.001) and stabilization thereafter (T3 vs. T4, p = 0.25). Higher Cmin levels at later timepoints were associated with improved clinical outcomes. Elevated Cmin correlated with a greater number of organ systems affected by irAEs. High baseline albumin and fewer comorbidities were predictors of higher Cmin.Conclusions: Pembrolizumab TDM is a feasible approach in NSCLC. Higher late-treatment Cmin levels may be associated with favorable outcomes, supporting pembrolizumab exposure as a potential biomarker and highlighting TDM as a tool for dose-tailoring strategies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1211-1220"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China. 从预算限制到基于价值的支付：中国晚期三阴性乳腺癌使用舒妥珠单抗替鲁莫替康的增量成本-效果分析

IF 3 3区医学

Expert Review of Anticancer Therapy Pub Date : 2026-09-01 Epub Date: 2026-05-06 DOI: 10.1080/14737140.2026.2668469

Shaohong Luo, Xiangzhen Wang, Lijing Yang, Shen Lin, Xiaoting Huang, Xiuhua Weng, Xiongwei Xu

{"title":"From budget constraints to value-based payment: an incremental cost-effectiveness analysis of sacituzumab tirumotecan for advanced triple-negative breast cancer in China.","authors":"Shaohong Luo, Xiangzhen Wang, Lijing Yang, Shen Lin, Xiaoting Huang, Xiuhua Weng, Xiongwei Xu","doi":"10.1080/14737140.2026.2668469","DOIUrl":"10.1080/14737140.2026.2668469","url":null,"abstract":"Background: Robust pharmacoeconomic evidence regarding the long-term affordability of sacituzumab tirumotecan (sac-TMT) in treatment of metastatic triple-negative breast cancer (TNBC) remains lacking. We evaluated the cost-effectiveness of sac-TMT versus chemotherapy for previously treated metastatic TNBC from the perspective of Chinese payers.Research design and methods: A partitioned survival model was developed using clinical efficacy and safety data from the OptiTROP-Breast01 trial. Key inputs included survival probability, incidence of adverse events, direct medical costs, and utility values. Total costs, quality adjusted life-year (QALY), and incremental cost-effectiveness ratio (ICER) were calculated as main outputs. Sensitivity analyses tested parameter uncertainty.Results: Sac-TMT provided an incremental survival benefit of 0.40 QALY compared to chemotherapy but incurred extra costs of $33,029.53. The corresponding ICER was $82,573.83/QALY, substantially exceeding the willingness-to-pay (WTP) thresholds of $40,343.68/QALY. Drivers of unaffordability were utility value of progressive disease, price of sac-TMT, and body weight. Probabilistic sensitivity analysis showed that the probability of sac-TMT being cost-effective was 0.68%, and price simulation manifested that a 77.5% price reduction for sac-TMT could make it economical.Conclusion: Sac-TMT is not cost-effective for metastatic TNBC compared to chemotherapy at current pricing. Significant price reductions are essential to justify its economic value in resource-constrained settings.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1201-1209"},"PeriodicalIF":3.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147766576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0